Modulation of P-glycoprotein function by St John's Wort extract and its major constituents

Pharmacopsychiatry

Volumn 37, Issue 6, 2004, Pages 292-298

  Weber, C C ^a   Kressmann, S ^a   Fricker, G ^b   Muller W E ^a,c  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Biocenter ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMENTOFLAVONE; BIAPIGENIN; CALCEIN; CYTOCHROME P450; FLUOXETINE; GLYCOPROTEIN P; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; HYPERIN; QUERCETIN; RUTOSIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG POTENCY; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN CELL; HYPERICUM PERFORATUM; IN VITRO STUDY; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADENOSINE TRIPHOSPHATE; AMITRIPTYLINE; ANIMALS; ANTIDEPRESSIVE AGENTS; BICYCLO COMPOUNDS; BRAIN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTHELIAL CELLS; FLUORESCEINS; FLUOXETINE; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; LEUKEMIA; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PHLOROGLUCINOL; PLANT EXTRACTS; QUERCETIN; SWINE; TERPENES;

EID: 9744267470     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832686     Document Type: Article

References (35)

1. Audus KL, Borchardt RT. Characterization of an In Vitro Blood-Brain Barrier Model System for Studying Drug Transport and Metabolism. Phamaceutical Research 1986; 3: 81-87
2. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother 2000; 34: 1013-1016
3. Bauer B, Miller DS, Fricker G. Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharm Res 2003; 20: 1170-1176
4. Beck WT, Mueller TJ, Tanzer LR. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 1979; 39(6 Pt 1): 2070-2076
5. Bendayan R, Lee G, Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech 2002; 57: 365-380
6. Biber A, Fischer H, Romer A, Chatterjee SS. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998; 31(Suppl 1): 36-43
7. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71: 163-169
8. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Nat Acad Sci USA 1989; 86: 695-698
9. Critchfield JW, Welsh CJ, Phang JM, Yeh GC. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 1994; 48: 1437-1445
10. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604
11. Feller N, Broxterman HJ, Wahrer DC, Pinedo HM. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 1995; 368: 385-388
12. Franke H, Galla H, Beuckmann CT. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res Brain Res Protoc 2000; 5: 248-256
13. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D et al. St John's Wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002; 53: 75-82
14. Hollman PCH. Evidence for health benefits of plant phenols: local or systemic effects. J Sci Food Agric 2001; 81: 842-852
15. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 2001; 59: 806-813
16. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338-345
17. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22: 46-54
18. Keller JH, Karas M, Muller WE, Volmer DA, Eckert GP, Tawab MA et al. Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem 2003; 75: 6084-6088
19. Linde K. MCD. St John's wort for depression (Cochrane Review). The Cochraine Library, 2004; (1)
20. Mitsunaga Y, Takanaga H, Matsuo H, Naito M, Tsuruo T, Ohtani H et al. Effect of bioflavonoids on vincristine transport across blood-brain barrier. Eur J Pharmacol 2000; 395: 193-201
21. Muller WE. Current St John's wort research from mode of action to clinical efficacy. Pharmacol Res 2003; 47: 101-109
22. Muller WE, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997; 30(Suppl 2): 102-107
23. Ott M, Bauer B, Cornelius M, Fricker G. Interactions of Hypericurn perforatum compounds with P-Glycoprotein at the blood-brain-barrier. Naunyn-Schmiedebergs Arch Pharmacol 2003; 367(Suppl 1): 8
24. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001; 134: 1601-1608
25. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000; 355(9203): 547-548
26. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994; 34: 459-64
27. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997; 8: 161-170
28. Schinkel AH. Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther 1998; 36: 9-13
29. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-2524
30. Shapiro AB, Ling V. Effect of quercetin on Hoechst 33 342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 1997; 53: 587-596
31. Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 1996; 7: 568-578
32. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380-387
33. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71: 414-420
34. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 2003; 305: 197-204
35. Wonnemann M, Singer A, Siebert B, Muller WE. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort. Pharmacopsychiatry 2001; 34(Suppl 1): S148-151